Preclinical support for tumor protein D52 as a cancer vaccine antigen
ABSTRACTOverexpressed tumor-associated antigens (TAAs) are a large group that includes proteins found at increased levels in tumors compared to healthy cells. Universal tumor expression can be defined as overexpression in all cancers examined as has been shown for Tumor Protein D52. TPD52 is an over...
Main Author: | Robert K. Bright |
---|---|
Format: | Article |
Language: | English |
Published: |
Taylor & Francis Group
2023-12-01
|
Series: | Human Vaccines & Immunotherapeutics |
Subjects: | |
Online Access: | https://www.tandfonline.com/doi/10.1080/21645515.2023.2273699 |
Similar Items
-
Tumor protein D52 (TPD52) affects cancer cell metabolism by negatively regulating AMPK
by: Yali Chen, et al.
Published: (2023-01-01) -
Analysis of the CD8+ IL-10+ T cell response elicited by vaccination with the oncogenic tumor-self protein D52
by: C. Riccay Elizondo, et al.
Published: (2020-06-01) -
miR-107 enhances the sensitivity of breast cancer cells to paclitaxel
by: Ma Changpo, et al.
Published: (2019-06-01) -
Cross talk of tumor protein D52 (TPD52) with KLF9, PKCε, and MicroRNA 223 in ovarian cancer
by: Khushbukhat Khan, et al.
Published: (2023-10-01) -
A novel TPD52L2-ROS1 gene fusion expanding the molecular alterations in inflammatory myofibroblastic tumor: case report and literature review
by: Xuguang Liu, et al.
Published: (2023-09-01)